Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Amgen Inc (AMGN)
Amgen Inc (AMGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 122,713,552
  • Shares Outstanding, K 534,327
  • Annual Sales, $ 26,323 M
  • Annual Income, $ 6,552 M
  • 60-Month Beta 0.64
  • Price/Sales 4.61
  • Price/Cash Flow 9.39
  • Price/Book 22.84
Trade AMGN with:

Options Overview Details

View History
  • Implied Volatility 19.96% ( +1.41%)
  • Historical Volatility 19.76%
  • IV Percentile 14%
  • IV Rank 22.45%
  • IV High 29.98% on 10/10/22
  • IV Low 17.06% on 05/05/23
  • Put/Call Vol Ratio 0.53
  • Today's Volume 7,847
  • Volume Avg (30-Day) 14,538
  • Put/Call OI Ratio 0.64
  • Today's Open Interest 130,441
  • Open Int (30-Day) 127,648

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate 4.46
  • Number of Estimates 9
  • High Estimate 4.84
  • Low Estimate 4.21
  • Prior Year 4.65
  • Growth Rate Est. (year over year) -4.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
211.71 +7.27%
on 06/01/23
231.95 -2.09%
on 06/16/23
+2.67 (+1.19%)
since 05/23/23
3-Month
211.71 +7.27%
on 06/01/23
256.44 -11.44%
on 04/10/23
-5.99 (-2.57%)
since 03/23/23
52-Week
211.71 +7.27%
on 06/01/23
296.67 -23.45%
on 11/08/22
-15.98 (-6.57%)
since 06/23/22

Most Recent Stories

More News
Moderating Inflation, a Tasty IPO, Bull Market Talk, and More

We've also got two stocks worth watching: Chevron and Burford Capital.

WMT : 155.46 (-0.19%)
CVX : 151.35 (-0.85%)
TGT : 131.83 (-0.42%)
JNJ : 165.48 (-0.08%)
CMG : 2,043.68 (-0.33%)
CRM : 210.09 (-1.50%)
CVS : 69.60 (+0.27%)
ORCL : 118.64 (-1.61%)
UNH : 477.00 (-0.43%)
SHOP : 63.79 (+0.49%)
SPOT : 157.49 (-1.01%)
ACI : 21.46 (-0.51%)
Alleged Industrial Espionage Makes an Interesting Story

We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment.

VRTX : 347.00 (-0.33%)
GOOGL : 122.34 (-0.66%)
AAPL : 186.68 (-0.17%)
GILD : 77.47 (-0.82%)
BIIB : 284.52 (-3.21%)
AMGN : 227.11 (-1.11%)
GOOG : 123.02 (-0.69%)
ASML : 697.89 (-2.72%)
CRSP : 56.03 (-1.60%)
KO : 61.20 (-1.05%)
TSM : 101.91 (-1.18%)
ABBV : 135.92 (-1.08%)
FDA GRANTS FULL APPROVAL FOR BLINCYTO® (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License...

AMGN : 227.11 (-1.11%)
AMGEN TO PRESENT AT THE GOLDMAN SACHS 44TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

/PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 44th Annual Global Healthcare Conference at 2:20 p.m. ET on Wednesday, June 14, 2023....

AMGN : 227.11 (-1.11%)
Is AbbVie or Amgen the Better Bargain Buy Right Now?

These elite drugmakers are both working through a number of headwinds.

TEVA : 7.62 (+0.93%)
ABBV : 135.92 (-1.08%)
AMGN : 227.11 (-1.11%)
HZNP : 102.56 (+1.15%)
Dow Stocks Like Microsoft, Apple, Disney, and Verizon Reveal Two Sides of the Market

Many well-known stocks are missing out on the market's epic 2023 rally.

T : 15.45 (-0.83%)
BA : 205.41 (-0.10%)
CAT : 234.44 (-1.22%)
TMUS : 132.80 (-1.15%)
NFLX : 424.02 (+0.36%)
HON : 200.09 (-0.28%)
COMP : 3.07 (-2.23%)
DJIA : 21.77 (-0.14%)
AMGN : 227.11 (-1.11%)
VZ : 35.51 (-0.95%)
MMM : 100.72 (+0.29%)
WBA : 31.40 (-1.54%)
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data from the CodeBreaK clinical trial program, the most comprehensive global...

AMGN : 227.11 (-1.11%)
Why AbbVie and Amgen Are Moving Lower Today

An ultra-low-priced biosimilar may negatively impact both biotechs.

ABBV : 135.92 (-1.08%)
AMGN : 227.11 (-1.11%)
Is Amgen a Good Dividend Stock?

The biotech's yield is near an all-time high right now.

AMGN : 227.11 (-1.11%)
HZNP : 102.56 (+1.15%)
AMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ACROSS ITS DIVERSE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023

New LUMAKRAS® (sotorasib) Data From First Study Evaluating Intracranial Efficacy of a KRAS G12C Inhibitor Versus Docetaxel in Treated KRAS G12C-Mutated...

AMGN : 227.11 (-1.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two...

See More

Key Turning Points

3rd Resistance Point 233.76
2nd Resistance Point 232.15
1st Resistance Point 229.63
Last Price 227.11
1st Support Level 225.50
2nd Support Level 223.89
3rd Support Level 221.37

See More

52-Week High 296.67
Fibonacci 61.8% 264.22
Fibonacci 50% 254.19
Fibonacci 38.2% 244.16
Last Price 227.11
52-Week Low 211.71

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar